Clinical Trials
22
Active:0
Completed:15
Trial Phases
4 Phases
Phase 1:14
Phase 2:4
Phase 3:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
Phase 1
14 (63.6%)Phase 2
4 (18.2%)Phase 3
3 (13.6%)Not Applicable
1 (4.5%)Pharmacokinetic/Pharmacodynamic Study of Vicagrel Capsules and Clopidogrel Tablets in Healthy CYP2C19 Normal Metabolizers
Not Applicable
Not yet recruiting
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 18
- Registration Number
- NCT07067775
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
The Mass Balance and Biotransformation Study of [14C] VC005 in Chinese Healthy Adult Male Volunteers
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: [14C]VC005
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 6
- Registration Number
- NCT06974292
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis
Phase 2
Recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: VC005 groupsDrug: VC005 Placebo group
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 114
- Registration Number
- NCT06891040
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Hospital of Skin Disease, Nanjing, Jiangsu, China
Phase III Clinical Study of VC005 Tablets in Adult Patients with Moderate to Severe Atopic Dermatitis
Phase 3
Recruiting
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Drug: VC005 low dose groupDrug: VC005 high dose groupDrug: VC005 Placebo group
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 480
- Registration Number
- NCT06723080
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Hospital for Skin Diseases, Nanjing, Jiangsu, China
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
Phase 3
Recruiting
- Conditions
- Locally Advanced Solid Tumor
- Interventions
- Drug: VC004 Capsules
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 54
- Registration Number
- NCT06658353
- Locations
- 🇨🇳
Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found